



PATENT
ATTORNEY DOCKET NO. 50291/016003

Certificate of Mailing: Date of Deposit: November 8, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence

Jeremy Waterman
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Christer Nordstedt et al.	Art Unit:	1631
Serial No.:	10/721,774	Examiner:	Michael L. Borin
Filed:	November 26, 2003	Customer No.:	21559
Title:	Peptide Binding the KLVFF-Sequence of Amyloid-Beta		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was mailed in connection with the above-captioned patent application on September 9, 2005, Applicants elect the invention of Group IV, claims 12-18, 30, and 33, with traverse.

Applicants respectfully submit that examination of certain claims in addition to those of Group IV would not result in an undue burden for the Examiner. In particular, claims 30 and 33 of Group IV are drawn to methods of inhibiting polymerization of an amyloid β peptide by use of a compound that falls within a specified formula. Similarly, claims 28 (Group II), 29 (Group III), and 31 (Group V) also are drawn to methods of inhibiting amyloid β polymerization by the use

of such a compound, and differ from claims 30 and 33 only by also specifying particular conditions associated with amyloid β polymerization (claim 28: hereditary cerebral hemorrhage; claim 31: Alzheimer's disease) or a result of amyloid β polymerization (claim 29: fibril formation). Searching these additional three claims would not be an extra burden, as any art relevant to these methods, which are more specific than those specified in claims 30 and 33, could be identified in a search relating to the subject matter of claims 30 and 33. Thus, because the subject matter of claims 28, 29, and 31 share in common with the subject matter of claims 30 and 33 the specification of inhibition of amyloid β polymerization, using compounds of the same formula, Applicants request reconsideration of the Restriction Requirement, so that claims 28, 29, and 31 are examined with the claims designated as being within Group IV (claims 30, 33, and 12-18).

With respect to the species election, Applicants elect for examination purposes the species of a compound including the following amino acid sequence: KLVFF, with traverse. Applicants respectfully submit that examination of a formula encompassing this sequence (e.g., KLX'F, with X' as defined in claim 30) and/or additional species (e.g., KLVF, KLVAf, and KLAFf) would not be unduly burdensome, given the relatedness of these sequences. Further, Applicants note that even in the case of sequences considered as independent and distinct inventions with respect to Restriction practice, the Office permits a "reasonable" number of sequences ("...in most cases, up to ten...") to be examined in a single application. M.P.E.P. § 803.04. In light of this, Applicants submit that examination of the formula KLX'F, as noted above, or at least the species in addition to KLVFF noted above, would not be unduly burdensome. Further, Applicants submit that special consideration should be given in cases such

as the present case, in which there are many highly related sequences, many of which have been tested.

Applicants respectfully request reconsideration of the Restriction Requirement, as is discussed above. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November 7, 2005

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045